Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The healing effect of over-the-counter wound healing agents applied under semiocclusive film dressing.

The British journal of dermatology·2014
Same author

Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf).

Archives of dermatology·2001
Same author

Tissue-engineered skin. Current status in wound healing.

American journal of clinical dermatology·2001
Same author

Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds.

Journal of the American Academy of Dermatology·2001
Same author

An octyl-2-cyanoacrylate formulation speeds healing of partial-thickness wounds.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2001
Same author

The pig as a model for human wound healing.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2001
Same journal

Fingolimod-associated lymphomatoid papulosis.

Actas dermo-sifiliograficas·2026
Same journal

Demodicosis: update and treatment with laser and other light sources.

Actas dermo-sifiliograficas·2026
Same journal

New treatments for adult female acne.

Actas dermo-sifiliograficas·2026
Same journal

First regulations of the Spanish Society of Dermatology (1909).

Actas dermo-sifiliograficas·2026
Same journal

Long-hair FUE: advantages and disadvantages of the most recent technique in hair transplantation.

Actas dermo-sifiliograficas·2026
Same journal

Sunburns, Tanning, and Social Media: A Descriptive Study Among Spanish University Students.

Actas dermo-sifiliograficas·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

Challenges encountered in dermatologic drug development.

W H Eaglstein1, K R Cash, G R Corcoran

  • 1weaglstein@stiefel.com

Actas Dermo-Sifiliograficas
|January 26, 2010
PubMed
Summary
This summary is machine-generated.

Developing new dermatology drugs faces significant hurdles. The primary barrier is the low economic potential and return on investment (ROI) for skin disease treatments, hindering novel therapy creation.

More Related Videos

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform
06:30

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform

Published on: May 17, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform
06:30

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform

Published on: May 17, 2021

Area of Science:

  • Dermatology
  • Pharmaceutical Development
  • Drug Discovery

Background:

  • Limited novel drug development for dermatologic diseases.
  • Numerous challenges impede the creation of new topical therapies.

Purpose of the Study:

  • To identify and discuss the key challenges in dermatology drug development.
  • To pinpoint the primary factor inhibiting novel dermatologic therapies.

Main Methods:

  • Review of factors influencing dermatologic drug development.
  • Analysis of economic, regulatory, and scientific considerations.

Main Results:

  • Economic potential and return on investment (ROI) are critical barriers.
  • Other factors include benefit-risk ratios, surrogate endpoints, drug penetration, stability, safety (irritancy, allergy, photosafety), formulation complexity, endpoint softness, and knowledge gaps.

Conclusions:

  • The low economic viability of skin disease treatments is the principal impediment to developing innovative dermatologic drugs.
  • Addressing economic challenges is crucial for advancing dermatology drug discovery.